Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7202)	11/20/1999 8:42:00 PM
From: Spekulatius	Read Replies (1) \| Respond to of 9719

MOGN - with 200M$ market cap,positive earnings and a cancer drug in Phase II, MOGN does not appear overvalued to me. The question is, if the money can be invested better elsewhere ... I am currently looking at GENZ, a stock I know quite well. I did not like it at 60$ but in the mid thirties, its well worth a look, IMHO.

To: Vector1 who wrote (7202)	11/21/1999 5:27:00 PM
From: David Cathcart	Respond to of 9719

V1, MOGN... If I remember correctly, you were mainly attracted to MOGN because of the promise of Salagen. If Salagen is still your main area of interest in the company, then you could argue that it was a successful investment, that sales of the drug may begin to taper off, and you may want to move on. On the other hand, if you see MOGN as a profitable company with an increasingly promising cancer treatment, then I'd say it is a premature and unfortunate time to pull the plug. Of course the key phrase in the last sentence is "increasingly promising." IMO, the degree to which you see promise in MGI-114 (now "irofulven") is the degree to which you will want to keep an investment in MOGN. I certainly could be wrong, but what I'm seeing on all fronts leads me to think investors will be very happy when PII results, and the company's strategy for FDA approval, are revealed during the first half of next year. My two cents regarding irofulven are: 1. For the time being, forget the infamous Euro deal; it will not be important until PIII. 2. Look at the few but promising PI and PII results seen thus far. 3. Look at the number of PII trials in progress covering a broad range of solid tumors. Only three of trials are sponsored by MGI Pharma. The NCI is sponsoring eight of the eleven PII trials and has committed to sponsoring at least three more. 4. Look at the increasing involvement between MGI Pharma and Pharmacia & Upjohn. My guess is that PNU will be the eventual Euro partner as well as potentially sharing the development and marketing of the fulvens in the U.S. I suppose they could also simply munch MOGN. Whatever you do, hats off to all for the overall performance of the VD Portfolio. I've benefited greatly from being a mostly silent lurker. David

To: Vector1 who wrote (7202)	11/21/1999 10:31:00 PM
From: RWReeves	Respond to of 9719

V1-Had the same inclination and acted on it. 114 looks OK, but thats about all that can be said for it and seems to be discounted in the stock price. Therefore, we have a "stationary target" that imo can be whacked by any bad news (haven't seen too much of that lately have we?)but is unlikely to be moved much by good news. Might be a good idea to cut back rather than close out. Congrats on sterling portfolio performance and excellent timing on SEPR. Those were probably my shares you were buying (sigh). RWR